Videos

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on how health systems can evaluate suzetrigine for acute pain pathways while balancing evidence, access, formulary sustainability, and pharmacist-led stewardship.

See how a team-based menopause clinic pairs pharmacists, gynecologists, and pelvic floor therapy to streamline care, screening, and symptom relief.

Learn how pharmacists open symptom-first menopause talks, weigh hormonal vs nonhormonal options, and counter social media myths.

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on why effective opioid stewardship in acute pain care must extend beyond prescription reduction to include multimodal analgesia, patient-centered outcomes, and standardized health-system pathways.

Yale's AZA Allsop, MD, PhD, on psychedelics as medicine versus wellness tools, and why naturalistic research settings matter for the field.

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on how multimodal, individualized care can improve acute pain management for opioid-tolerant patients and those receiving buprenorphine or methadone.

The panelists examined how early recognition of TD allows providers to optimize antipsychotic therapy and minimize or eliminate anticholinergic medications before patients progress to higher-burden treatment options such as clozapine.

In this episode, 'Planning Before the First Dose: Pre-Treatment Transition Strategies for Bispecific Antibody Therapy in Myeloma,' the oncology pharmacists explore the following question: 1. Transition planning needs to begin before the first dose is administered, not after step-up dosing is complete. What does that pre-treatment planning look like at your institution?

Tynosynovial giant cell tumor (TGCT) is a rare, locally aggressive condition that significantly impacts patient quality of life and function, yet many patients wait years for diagnosis and may endure multiple surgeries with higher recurrence rates. In this series, Sasha Watson, PharmD (Sylvester Comprehensive Cancer Center) and Alexis Tandyk, PharmD, BCOP (University of Colorado Health), discuss CSF1R inhibitors, the targeted approach transforming TGCT management. They review the pathophysiology and disease burden context, clinical trial evidence from MOTION and ENLIVEN, strategies for differentiating between CSF1R agents, proactive toxicity management frameworks, and practical steps for building a systematic, pharmacist-led TGCT care model.

Stephen Saklad, Melissa Cloyd, Jamie Kneebusch, and Farah Khorassani discussed the importance of ongoing provider re-education on TD, noting that many clinicians remain unfamiliar with the condition and its presentation, particularly given that effective vesicular monoamine transporter 2 (VMAT2) inhibitor treatments have only been available since 2017.

Welcome back to another Pharmacy Times Practice Pearls series. In this episode titled, 'Transitions of Care in Multiple Myeloma: Why Handoffs Remain the Biggest Operational Challenge,' Zahra Mahmoudjafari led the conversation about the following question: 1. Transitions of care has emerged as the single most consistent operational challenge, outranking efficacy and safety concerns. Why is this difficult, and where are the pain points?

Learn how pharmacists guide AML care, from patient education to mutation-targeted menin inhibitors like revumenib and ziftomenib.

A compliance expert outlines what's next for GLP-1 compounding oversight and how pharmacists can stay audit-ready.

Timothy Clifford, PharmD, outlines how quality-of-life impact, comorbid conditions, and prior therapy failures guide biologic selection for CRSwNP.

Aderonke Adeboye, PharmD, discusses the clinical red flags that signal a patient with CSU needs advanced therapy and how specialty pharmacists guide treatment selection and support long-term adherence for biologics and emerging oral agents.

Learn how new nonhormonal menopause drugs ease hot flashes, improve sleep, and who benefits—plus key side effects and liver monitoring.

Phase 3 SKYLIGHT and OASIS trials show rapid relief of menopausal hot flashes—often within one week—plus strong safety data, with sleep outcomes under close study.

GoodRx's David Graziano breaks down how fluctuating acquisition costs, narrow formularies, and retrospective reimbursement adjustments are squeezing independent pharmacies—and what solutions exist to help them remain competitive.

Monica Dougherty, PharmD, BCACP, explains how the 2026 GOLD guideline updates use blood eosinophil counts to guide biologic therapy decisions for patients with COPD.

Pharmacy Times speaks with Caitlin Jones, PHD, on how evidence gaps, opioid dependence, and misaligned incentives can undermine pain care.

Suzanne Feeney, PharmD, explains why expanding clinical services—from immunizations to chronic disease management—is a critical growth strategy for independent pharmacies navigating reimbursement pressures and shifting legislation.

Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about who should carry naloxone, common misconceptions surrounding overdose reversal and fentanyl-related overdoses, and the broader strategies needed to reduce overdose deaths.

Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about the FDA's expansion of over-the-counter naloxone access, remaining barriers to availability, and the critical role pharmacists play in overdose prevention and patient education.

A compliance expert breaks down the FDA's move to exclude glucagon-like peptide-1 (GLP-1) drugs from the 503B bulk's list and what it means for pharmacists and patients.

Shahida Choudhry, PharmD, discusses earning McKesson ideaShare's inaugural Trailblazer Award, building an integrated primary care and pharmacy model, and using advocacy and social media to elevate independent pharmacy.

Chiadi Ndumele, MD, breaks down the cardiovascular-kidney-metabolic syndrome (CKM) guideline's glucagon-like peptide-1 (GLP-1) and kidney-protective therapy guidance—and the pharmacist's role in coordinated care.

In this interview, Chris Elder, PharmD, BCOP, discusses major themes from OPC 2026, including advances in immunotherapy delivery, practical applications of ASCO and EHA data, and the expanding role of oncology pharmacists in optimizing patient care.

In this interview, Sonia Amin Thomas, PharmD, BCOP, AFMCP, INHC, discusses common challenges in precision medicine implementation and how oncology pharmacists can build expertise in biomarker interpretation, pharmacogenomics, and multidisciplinary care.

Findings from a retrospective analysis show that montelukast prophylaxis significantly reduced rituximab infusion-related reactions, particularly among patients receiving treatment for oncology indications.

Pharmacy Times speaks with Caitlin Jones, PHD, on opioids, spinal cord stimulators, and treatment-related harms in chronic low back pain.